Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Tango Therapeutics (TNGX) Revenue (2020 - 2025)

Tango Therapeutics has reported Revenue over the past 6 years, most recently at $53.8 million for Q3 2025.

  • Quarterly results put Revenue at $53.8 million for Q3 2025, up 363.61% from a year ago — trailing twelve months through Dec 2025 was $62.4 million (up 48.29% YoY), and the annual figure for FY2025 was $62.4 million, up 48.29%.
  • Revenue for Q3 2025 was $53.8 million at Tango Therapeutics, up from $3.2 million in the prior quarter.
  • Over the last five years, Revenue for TNGX hit a ceiling of $53.8 million in Q3 2025 and a floor of $3.2 million in Q2 2025.
  • Median Revenue over the past 5 years was $6.4 million (2022), compared with a mean of $10.7 million.
  • Peak annual rise in Revenue hit 363.61% in 2025, while the deepest fall reached 83.99% in 2025.
  • Tango Therapeutics' Revenue stood at $5.7 million in 2021, then grew by 12.16% to $6.4 million in 2022, then fell by 15.29% to $5.4 million in 2023, then fell by 24.19% to $4.1 million in 2024, then skyrocketed by 1207.04% to $53.8 million in 2025.
  • The last three reported values for Revenue were $53.8 million (Q3 2025), $3.2 million (Q2 2025), and $5.4 million (Q1 2025) per Business Quant data.